Replies to post #513595 on NorthWest Biotherapeutics Inc (NWBO)

[Dr Bala]

Confounding after a highly successful P3 trial is an impossible task.

[biosectinvestor]

This was an adaptive trial and was regardless addressed prior to the end of the trial, pursuant to regulation and previous to unblinding. They switched from a more common but fast accumulating endpoint that was a surrogate for survival to Actual Survival, which takes a very long time to accumulate as data. They delayed the end of the trial therefore for a very long time to accumulate REAL data on survival rather than data estimated to possibly predict data.

The use of an external control arm, and crossover to distinguish newly diagnosed versus recurrent Glioblastoma address the issue of confoundment with regard to the drug being so successful that everyone wanted to get the drug in the crossover arm, eliminating the placebo arm.

While the details will no doubt be discussed and any issues that may arise, because they measured a real outcome, survival, the actual benefit will be virtually impossible to ignore. So, you’re incorrect, as always, on a countless array of details. At least you stopped saying some of the false things you usually say to make the outcome a given.

[Roman516]

Sorry, there are some people who rebuke NWBO. In this case, confounding might cause illusion of understanding since humans get used to come to a quick conclusion based on very limited observations. In the case of NWBO, many doctors, scientist, and professionals are very impressed with the data results for DCVax-L. However, an armature who is confounded can post misleading information in the hope that the reader will believe them, but the reality is that they have no real basis but only their opinion. Hence, it is very important to remain focused and understand again that there are doctors, scientist, and professionals are very impressed with the data results for DCVax-L. This supersedes all other false comments by confounded individuals who have no real clue whatsoever. NWBO is moving forward based on the fact that the data is well accepted, and that is the bottom line.